BIOSECURE Act Reshapes Biopharma Supply Chains, Driving API and Oligo CDMO Expansion in South Korea

CHOSUNBIZ South Korea

Overview

The U.S. BIOSECURE Act is catalyzing a significant shift in biopharmaceutical supply chains away from China, creating substantial opportunities for South Korean contract development and manufacturing organizations (CDMOs). Initially focused on large biologics CDMOs, this impact now extends to small-molecule active pharmaceutical ingredient (API) and high-value oligonucleotide (oligo) contract manufacturing. With restrictions on Chinese firms tightening from 2028, South Korean companies like ST Pharm are seeing steady inquiries and are poised to become critical alternative hubs, particularly for essential RNA-based therapeutic components.

In Depth

Background and the Impetus of the BIOSECURE Act

The U.S. BIOSECURE Act represents a pivotal legislative initiative aimed at de-risking the biopharmaceutical supply chain by reducing reliance on Chinese biotechnology companies. This act, driven by geopolitical and economic security concerns, threatens to restrict U.S. federal funding to entities that engage with certain Chinese biotech firms, compelling global pharmaceutical companies to reassess and diversify their supplier strategies.

Initially, discussions around the act’s impact primarily centered on large biologics CDMOs, given the dominant role of Chinese players like WuXi Biologics in antibody drug production. However, its ripple effects are now broadening to encompass the manufacturing of small-molecule active pharmaceutical ingredients (APIs) and high-value oligonucleotides, thereby opening new strategic avenues for South Korean CDMOs.

Expanded Opportunities for South Korean CDMOs

The BIOSECURE Act is positioning South Korean CDMOs as critical alternative hubs within the pharmaceutical supply chain, particularly in:

• API Contract Manufacturing: Beyond the large biologics CDMOs, domestic API contract manufacturers such as Yuhan Chemical Inc. and ST Pharm are gaining prominence. These companies are experiencing consistent inquiries from global drugmakers, with potential for significant new order wins in the second quarter of 2026 as firms seek to diversify their API sources.
• Oligonucleotide CDMO: ST Pharm, in particular, is strategically focusing on high-value oligonucleotide CDMO services. Oligonucleotides are essential components for RNA-based therapies, including mRNA vaccines and antisense oligonucleotides, and their manufacturing requires highly specialized expertise and facilities. This niche positions Korea as a key alternative for these complex and critical raw materials.

While the BIOSECURE Act grandfathers existing contracts with Chinese entities until 2032, it is anticipated to impose strict limitations on Chinese corporations’ participation in new U.S. projects and contract renewals starting in 2028. This impending regulatory shift is a primary driver behind the steady increase in inquiries directed towards Korean companies.

Industry Impact and Future Outlook

This restructuring of the biopharmaceutical supply chain is expected to have long-term implications for the global ecosystem. South Korea, with its advanced manufacturing capabilities, stringent quality control systems, and strategic geographic location, is well-positioned to strengthen its role as a crucial alternative manufacturing hub to China.

• Diversification and Resilience: Pharmaceutical companies globally are moving to diversify their supplier base to mitigate future risks, making South Korea an increasingly attractive and reliable partner. This enhances the resilience of the global pharmaceutical supply chain.
• Technological Innovation and Specialization: Korean CDMOs are expected to accelerate their technological innovation and capacity expansion in high-value, specialized areas such as oligonucleotide synthesis, further solidifying their expert niche.
• Geopolitical Significance: Biopharmaceutical manufacturing is increasingly recognized as vital for national and economic security. Regulations like the BIOSECURE Act will continue to drive the strategic reorganization of global supply chains, emphasizing the importance of securing critical manufacturing capabilities within allied nations.

South Korean CDMO firms are poised to capitalize on this geopolitical inflection point, showcasing their manufacturing prowess and technological leadership to the world. They will likely continue to expand their strategic partnerships and exert greater influence in the global biopharmaceutical market, particularly in Asia, ensuring a more diversified and secure future for advanced therapy production.